Capability expansion for generic medicine manufacturing and R&D.

Germany-based company to build a 60,500-square-foot manufacturing facility dedicated to producing critical injection-molded components for medical devices and pharmaceutical packaging, as well as desiccant solutions

Announced plans to build a new biologics manufacturing facility as part of long-term growth strategy. The project is expected to have about a $5 billion economic impact, creating about 300 permanent high-skill jobs and over 500 construction jobs.

New research and manufacturing facility, supporting vertical integration of Ratio's current and future pipeline of next-generation radiopharmaceuticals.

Substantially increasing spending on U.S. R&D. Sanofi also announced plans to expand U.S.  manufacturing capacity, both through direct investments in Sanofi sites, as well as through partnerships with other domestic manufacturers, to help ensure the production of medicines in the U.S.

Expanding its campus into a major hub for manufacturing continuous glucose monitoring (CGM) systems for diabetes management and adding a new diagnostics production facility. 

The expansion is expected to create “hundreds” of skilled manufacturing jobs and thousands of construction jobs in Indiana. 

The first East Coast manufacturing site for Genentech (Roche’s U.S. subsidiary) is a fill-finish biologics plant that will produce metabolic medicines, including next-gen obesity treatments, to support growing demand.

The project is part of Roche’s $50B U.S. initiative and will create more than 400 local full-time jobs when operational (2029) and about 1,500 construction jobs during development.

Investing in U.S. operations over the next five years to upgrade and improve U.S. manufacturing sites.

Gilead announced an $11 billion U.S. investment initiative (supplementing $21 billion already planned through 2030) to expand its domestic manufacturing and R&D footprint. About $4 billion will go into capital projects: three new facilities and three upgraded sites to boost U.S. production and lab capacity.

Gilead estimated this phase will create about 800 new U.S. jobs and over 2,200 indirect jobs by 2028.

A U.S. investment pledge across five years to expand research, technology, and manufacturing capabilities. BMS seeks to gain control over complex supply chains, ensuring its medicines are made closer to the patients who need them.